Probably, HER2(–) patients becoming HER2(+) in the residual tumors due to tumor heterogeneity neutralizes the HER2 loss effect of NACTx and prevents the statistical significance of NACTx on HER2 discordance (10.8%; p = 0.76). Here, ERBB2 is linked to neoplasm.